NASH limits anti-tumour surveillance in immunotherapy-treated HCCDominik Pfister, Florian Hucke, Jan Kosla et al.|Nature|2021Cited by 1.3k
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trialRoser Pinyol, Josep M. Llovet, Robert Montal et al.|Gut|2018Cited by 338
Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinomaDaniela Sia, Josep M. Llovet, Bojan Losic et al.|Nature Communications|2015Cited by 302
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinomaRobert Montal, Josep M. Llovet, Daniela Sia et al.|Journal of Hepatology|2020Cited by 301
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classificationCarla Montironi, Josep M. Llovet, Florian Castet et al.|Gut|2022Cited by 245